Harbour Investments Inc. Has $53,000 Position in IDEXX Laboratories, Inc. $IDXX

Harbour Investments Inc. increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 98 shares of the company’s stock after acquiring an additional 21 shares during the period. Harbour Investments Inc.’s holdings in IDEXX Laboratories were worth $53,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of IDEXX Laboratories by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock valued at $4,139,001,000 after acquiring an additional 146,427 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after acquiring an additional 825,965 shares in the last quarter. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 0.5% during the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock valued at $489,832,000 after acquiring an additional 5,418 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after acquiring an additional 414,802 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of IDEXX Laboratories by 37.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock valued at $452,046,000 after acquiring an additional 290,551 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.4%

Shares of NASDAQ IDXX opened at $640.85 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The company has a market cap of $51.27 billion, a PE ratio of 53.36, a P/E/G ratio of 4.13 and a beta of 1.58. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $638.40 and a two-hundred day moving average of $557.79.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm posted $2.44 earnings per share. The company’s revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Leerink Partners boosted their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Piper Sandler restated a “neutral” rating and issued a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $656.50.

Insider Buying and Selling

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the transaction, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at approximately $52,650,885.78. The trade was a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director directly owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,057 shares of company stock valued at $34,293,468. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.